First CAR-T therapy to target BCMA gets FDA nod
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Common side effects of Abecma such as CRS and ICANS were mostly low grade.
“Common side effects such as CRS and immune effector cell-associated neurotoxicity syndrome (ICANS) were mostly low grade, indicating manageable toxicity.”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [259]
The median duration of response to Abecma was 11 months in patients achieving CR and 19 months in those achieving sCR.
“The median duration of response (mDOR) was 11 months in patients achieving CR and 19 months in those achieving stringent complete response (sCR).”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [259]
In the KarMMa study involving 128 RRMM patients, the ORR to a single infusion of Abecma was 73%, with a CR rate of 33%.
“In the KarMMa study involving 128 patients with RRMM, the overall response rate (ORR) to a single infusion of Abecma was 73%, with a complete response (CR) rate of 33%.”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [259]
Abecma has demonstrated the ability to induce rapid, deep, and long-lasting remissions with just one infusion.
“Abecma has demonstrated the ability to induce rapid, deep, and long-lasting remissions with just one infusion, providing a new and effective personalized therapy option for MM patients [227, 243, 258, 259].”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [259]
Cited by
Sorted by citations
Multiple myeloma: signaling pathways and targeted therapy
Lu, Q., Yang, D., Li, H., Niu, T., & Tong, A. (2024) · Molecular biomedicine · doi:10.1186/s43556-024-00188-w · Cited by 90 · see citing works
- Venue
- Nature Biotechnology
- Published
- 2021-05
- Volume
- 39
- Issue
- 5
- Pages
- 531-531
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W4206554752
- Cited by
- 15
- References
- 0
- Citations by year
- 2025: 1 · 2024: 2 · 2023: 2 · 2022: 8 · 2021: 2
- Type
- other
- Language
- en
- Open access
- closed
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- CAR T-cell therapy, BCMA, bispecific T-cell engagers, FDA approval, multiple myeloma, regulatory approval
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
